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Resveratrol may function as a chemopreventive agent.. A recent clinical study demonstrates a 
reduction in tumor cell proliferation in colorectal patients receiving repeated oral ingestion of 
resveratrol. However, gaps remain in our knowledge of the molecular mechanisms by which 
resveratrol exerts its chemopreventive effect. We have previously demonstrated that 
resveratrol induces apoptosis in colon cancer cells and that resveratrol can sensitize 
chemoresistant colon cancer cells to various drugs. Based on its ability to activate PPARγ 
(Peroxisome Proliferator-Activated Receptor gamma) in colon cancer cells, we sought to 
determine the implication of this nuclear transcription factor in resveratrol-induced apoptosis. 
Methods and results 
Transient transfection of cancer cells with a dominant-negative PPARγ mutant or treatment 
with a PPARγ antagonist (GW9662) reversed the inhibitory effect of resveratrol. Moreover, 
GW9662 prevented disruption of the cell cycle induced by resveratrol and consequently 
abrogated resveratrol-induced apoptosis. Tumor cell death was potentiated by combining 
resveratrol with rosiglitazone, a PPARγ agonist, supporting the notion that combining a 
resveratrol/PPARγ agonist could be a promising pharmacological approach for treatment of 
colorectal cancer. 
Conclusion 
Altogether, the results show that PPARγ could mediate a part of the chemopreventive activity 
of RSV in colon cancer and the combination of RSV with PPARγ modulators. 
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1. Introduction 
Generally speaking, the prevention of tumor development is more relevant than treating 
established disease. Avoidance of risk behaviors remains the most efficient approach for 
cancer prevention, but the development of active strategies such as the consumption of 
chemopreventive agents is another area of intense investigation. Among these compounds, 
natural products such as dietary polyphenols have demonstrated promising properties through 
epidemiological and experimental studies [1-3]. Resveratrol (trans-3,4′,5-trihydroxystilbene, 
RSV), a wine grape microcomponent, appears to be one of the most efficient polyphenols [4] 
because it may prevent the occurrence of vascular diseases, neurodegenerative processes and 
some malignant tumors (see for review [5, 6]). These preventive actions of resveratrol have 
been extensively studied in colon carcinoma models, both in vitro [5, 7, 8] and in vivo [6, 7, 
9]. In particular, ingestion of RSV was observed to reduce the number of preneoplastic lesions 
as well as the incidence and multiplicity of tumors in animal models [9, 10]. Most 
importantly, clinical trials have been launched in cancer patients (registered in 
www.ClinicalTrials.gov). Several phase I/II clinical trials are currently underway for 
resveratrol, including National Cancer Institute-sponsored studies at the University of 
Michigan in the US and the University of Leicester in the UK. In this last study, Brown’s 
team has shown in a phase I/II clinical trial that the levels of RSV and RSV metabolites 
(sulfate and glucuronides) measured in human colorectal tissue after repeated oral ingestion of 
1 g for 8 days were correlated with a 5% reduction in tumor cell proliferation, confirming the 
potential anticarcinogenic properties of RSV [11]. 
At the molecular and cellular level, we and others have previously demonstrated that the 
ability of RSV to prevent the occurrence of colon carcinomas is related to the inhibition of the 
tumor cell cycle [12, 13] and to the induction of cell death in colon cancer cells [14]. To 
trigger these effects, RSV accumulates in plasma membrane lipid rafts, enters the cancer cell 
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by endocytosis and activates the mitogen-activated protein kinase (MAPK) pathway [15]. 
Thus, MAPK integrin αvβ3 complexes are activated, which subsequently play important roles 
in apoptosis induced by RSV [15]. Nevertheless, disruption of lipid rafts and inhibition of the 
integrin αvβ3 complexes did not completely abolish the effect of RSV, suggesting that there 
are other actors playing a role in the molecular effect [15]. Among the different potential 
candidates, the nuclear transcription factor PPARγ (Peroxisome Proliferator-Activated 
Receptor gamma) could be another essential target for mediating some of RSV’s effects. In 
support of this hypothesis, a previous report established that the activation of the 
spermidine/spermine N(1)-acetyltransferase (SSAT), which is a rate-limiting enzyme in 
polyamine catabolism, is induced by RSV through a PPARγ-dependent mechanism [8]. This 
RSV-dependent PPARγ activation seems to be mediated, at least partly, by the activation of 
the ligand-binding domain (LBD/AF2) of the nuclear receptor [8]. Yet, the role of PPARγ in 
RSV-induced cell death and in its chemopreventive properties remains ill-defined and 
deserves further investigation. 
In the present study, we addressed a new role of PPARγ in RSV-induced apoptosis and 
in RSV-induced proliferation inhibition in colon carcinoma cells. Using a specific PPARγ 
antagonist and a dominant negative mutant form of PPARγ, it was shown that this receptor is 
required for 1) RSV-induced accumulation of colorectal tumor cells in the S phase of the cell 
cycle and 2) RSV-induced inhibition of colon cancer cell viability. Combined, these events 
contribute to the induction of colon cancer cell apoptosis. Notably, the combination of RSV 
with a PPARγ agonist, namely rosiglitazone, increases the ability of RSV to induce colon 
cancer cell death.  
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2. Materials and methods 
2.1. Cell lines, expression vectors and transient transfections 
Human colon carcinoma cell lines SW480, HCT116, Caco2 and SW620 were obtained from 
the American Tissue Culture Collection (ATCC, Rockville, MD, USA) and were maintained 
in RPMI 1640 medium, (Biowhittaker Co., Fontenay-sous-Bois, France) supplemented with 
10% fetal calf serum and 2 mM L-glutamine (Biowhittaker). The vectors used for 
transfections include pcDNA3 (Invitrogen) as an empty vector for control transfection, and 
plasmid pcDNA3-PPARγ L468A/E471A, a dominant-negative double mutant (a kind gift 
from Prof. V.K. Chatterjee, Department of Medicine, University of Cambridge, 
Addenbrooke’s, Cambridge, UK) [16]. Exponentially growing cells were incubated with a 
mixture of 9 µL Fugene (Roche Diagnostics Corporation, Indianapolis, IN, USA) with 1 µg of 
the above-indicated plasmid together with 1 µg of an EGFP-encoding plasmid (pEGFP-C1, 
Clontech, Palo Alto, CA, USA). Transfected cells were treated 24 h later for indicated times 
before measuring the number of EGFP-positive, survival and apoptotic cells. 
 
2.2 Drugs, chemical reagents and antibodies 
Trans-resveratrol (RSV), propidium iodide and Hoechst 33342 were obtained from Sigma-
Aldrich (St-Quentin-Fallavier, France). We used rabbit polyclonal antibodies (Abs) against 
human caspase-3 active form from Cell Signalling Technologies (Beverly, MA, USA) and 
mouse monoclonal Ab against β-actin from Sigma-Aldrich (St-Quentin-Fallavier, France). 
GW9662 and rosiglitazone were purchased from Bertin Pharma (Montigny-le-Bretonneux, 
France). The PPARα antagonist, GW6471, and the PPARβ/δ antagonist, GSK0660, were 
purchased from Sigma-Aldrich. 
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2.3. Cell viability measurements 
Colon carcinoma cells were seeded 24 h before treatment into 24 well plates in complete 
growth medium. The next day, cells were challenged for 24 and 48 h with RSV at 30 µM, a 
concentration for which RSV induces cell proliferation inhibition in colon cancer cell lines 
without toxicity in normal cells [12, 13, 15]. All control and treated cells received the same 
volume of ethanol (0.1%). After the indicated times, cells were harvested and the number of 
viable cells was quantified with a hemocytometer by the trypan blue exclusion test as 
previously described [13]. 
 
2.4. mRNA extraction and gene expression analysis by real-time qRT-PCR 
Total RNA from untreated SW480, SW620, HCT116 and Caco-2 cells were extracted using 
Trizol reagent (Invitrogen) according to the manufacturer’s instructions. One microgram of 
RNA was reverse-transcribed using the M-MLV Reverse Transcriptase kit (Invitrogen) 
according to the manufacturer’s instructions to produce cDNA. RT-qPCR was performed 
using the Power SYBR® Green PCR Master Mix kit (Applied Biosystems), according to the 
manufacturer’s protocol, with a 7500 Fast Real-Time PCR system (Applied Biosystems). The 
following primers were used: β-actin (housekeeping gene) forward 5′- 
CTTCCTGGGCATGGAGTC-3′, reverse 5′- GCCAGGGTACATGGTGGT-3′; PPARγ1: 
forward 5′-AAAGAAGCCAACACTAAACC-3′, reverse 5′-CTTCCATTACGGAGAGATCC-3′; 
PPARβ/δ:forward 5′-TGGCTTTGTCACCCGTGAGT-3′, reverse 5′-
CAGAATGATGCCGCAATGAA -3′; PPARα : forward 5′-AGAACAAGGAGGCGGAGGT -3′, 
reverse 5′-TCAGGTCCAAGTTTGCGAAGC -3′. Samples (triplicates for each cell line) were 
incubated at 95°C for 5 min for denaturation followed by 40 cycles of denaturation at 95°C 
for 15 s and combine annealing and extension at 60°C for 1 min. Amplification of specific 
transcripts was confirmed by melting curves obtained at the end of each PCR run. Standard 
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curves were generated from pooled cDNA of assayed samples. All PCR efficiencies were 
between 95 and 105%. The relative changes in gene expression were determined using the 
ΔΔCT method. Fold change was calculated as 2-ΔΔCT. 
 
2.5. Flow cytometric analysis of cell cycle 
Cells were seeded 24 h before treatment into 25-cm2 flasks. After treatment, the detached and 
adherent cells were pooled, fixed with ethanol and stained with propidium iodide (PI) as 
previously described [17] for subsequent analyses with a CyFlow Green flow cytometer, and 
the fluorescence of PI was detected above 630 nm. For each sample, 20,000 cells were 
acquired. Furthermore, data were analyzed with MultiCycle software (Phoenix Flow Systems, 
San Diego, CA, USA); the x-axis corresponds to the DNA content and the y-axis to the 
number of cycling cells. The maximum value on the y-axis is inversely proportionate to the 
altered cells level (non-cycling cells), which were excluded by gating. 
 
2.6. Apoptosis identification 
Cells were seeded into six-well plates 24 h before treatments. Then cells were untreated (Co) 
or treated with either RSV alone (30 or 50 µM) or in combination with PPARγ antagonist 
GW9662 (5 µM) for 48 h. Transiently transfected cells with either empty plasmid (pcDNA3) 
or a plasmid encoding a double dominant-negative mutant of PPARγ (PPARγ/DN) were 
treated 24 h after transfection with RSV at 30 µM (R30) or 50 µM (R50) or the vehicle (Co). 
After incubation time periods, supernatants of each well were collected and the adherent cells 
were recovered by trypsinization with 1 mL of trypsin/EDTA solution. Suspensions 
containing supernatant and trypsinized cells were washed with PBS 1X and then stained with 
1 µg/mL Hoechst 33342 (Sigma-Aldrich) for 15 min at 37°C. Cells were then mounted onto 
glass slides and observed with a light microscope (Zeiss, Germany). Percentages of apoptotic 
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cells presenting typical nuclear chromatin condensation and fragmentation were determined 
by analyzing 300 cells from randomly selected fields. 
 
2.7. Immunofluorescence studies 
Tumor cells were seeded into tissue culture chambers at 20,000 per well (Chamber Slide, Life 
Technologies Co.) for 24 h, then treated and subsequently fixed in 2% paraformaldehyde 
(Sigma-Aldrich, Chemical Co.) for 10 min at 4°C, washed twice with PBS for 10 min, 
preincubated with 1% bovine serum albumin for 15 min at room temperature, and incubated 
with the primary Ab (PBS, 0.1% saponin, 0.5% bovine serum albumin) for 2 h at room 
temperature. After washing, cells were incubated for 30 min with 488-alexa goat anti-rabbit 
(Molecular Probes, Eugene, OR, USA). Nuclei were stained with Hoechst 33342. Analysis 
was made using a fluorescence microscope (Nikon, Champigny, France). A nonrelevant 
isotype-matching Ab was used as negative control (not shown). 
 
2.8. Chemosensitization assays 
Colon cancer cells were seeded 24 h before treatment into 24-well plates. The next day, cells 
were left untreated or pretreated in triplicate wells with RSV (10 µM) for 24 h and then 
challenged for additional 24 h with rosiglitazone. We have previously shown that RSV at 10 
µM was able to sensitize colon cancer cells to various chemical drugs [12, 18, 19]. After 
treatments, cells were washed with PBS and then stained with crystal violet (0.5% (w/v) for 5 
min and then rinsed twice with water. Absorbance was read at 540 nm after extraction of the 
dye by 0.1 M sodium citrate in 50% ethanol. 
 
2.9. Statistical analyses 
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Data are expressed as means ± SD (n=6) of at least three independent experiments. The 
significance of differences was established with Student’s paired t-test. Values of p<0.05 were 
considered significant. 
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3. Results 
3.1. Resveratrol-induced colon cancer cell death is prevented by PPARγ  antagonists or 
by PPARγ  dominant-negative expression. 
We exposed four human colon cancer cell lines, namely Caco-2, HCT-116, SW480 and their 
metastatic phenotype SW620 to 30 µM RSV for 24 h before evaluating cell viability (Fig. 
1A). The RSV concentration was chosen in agreement with our previous results showing a 
marked antiproliferative and proapoptotic effect on various tumor cell lines [12, 17, 20] 
without any toxic effect on normal human monocytes and rat intestinal IEC18 cells [15]. As 
revealed by the trypan blue exclusion viability test, 30 µM RSV (R30) strongly decreases cell 
viability of the four tumor cell lines, in as little as 24 h and is reinforced at 48 h (Fig. 1A). 
In order to analyze the potential role of PPARγ in the antiproliferative activity of RSV 
in colon cancer cells, we used the potent irreversible and selective PPARγ antagonist 2-
chloro-5-nitrobenzanilide (GW9662) in the presence and absence of RSV (Fig. 1A). As 
GW9662 itself has growth-inhibitory properties [21], we used it at 2.5 and 5 µM, 
concentrations where GW9662 acts as a potent antagonist of PPARγ in the cell [22]. GW9662 
covalently modifies Cys(285) and does not affect the transcription of full-length PPARα and 
PPARδ and consequently does not interfere with the signaling pathways modulated by 
PPARα and PPARδ [21, 22]. This PPARγ inhibitor dose-dependently prevented RSV-induced 
death of the four colon cancer cell lines in the same manner at 24 and 48 h (Fig. 1A). 
Interestingly, increasing the concentration of GW9662 up to 5 µM in Caco-2 cells further 
inhibited RSV-induced cell death, which was not observed with the other cell lines where no 
differences were seen between 2.5 µM or 5 µM of PPARγ antagonist (Fig. 1A). These 
differences were strengthened at 48 h of treatment. Indeed, it seems that in SW480, S620 and 
HCT116 cells, PPARγ is yet fully blocked by 2.5 µM of GW9662, whereas dose-dependent 
inhibition is observed in Caco-2 cells with pronounced differences between 2.5 and 5 µM 
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(Fig. 1A). A potential explanation could be provided by the analyses of PPAR expression 
levels in the different cell lines tested. Indeed, qPCR analyses show that compared to the three 
other cell lines, Caco-2 cells express PPARγ more strongly, as revealed by the mRNA levels 
(Supporting information Fig. S1). This result may explain why a concentration-dependent 
effect is more visible in Caco-2 cells than in the other tumor cell lines (SW480, SW620 and 
HCT116) after 48 h of treatment, where the nuclear factor PPARγ is probably saturated by the 
antagonist GW9662. 
To further assess the role of PPARγ in this death pathway, we transiently transfected 
SW480 colon cancer cells with constructs encoding a double dominant-negative mutant of 
PPARγ that retains its ligand and DNA-binding properties [16]. We showed that transient 
expression of PPARγ/DN protects colon cancer cells from RSV-induced cell death (Fig. 1B) 
to a similar extent as 5 µM GW9662 (Fig. 1A). Notably, these cell lines also express PPARα 
or PPARβ/δ (Supporting information Fig. S1). Indeed, quantification by qPCR of the different 
PPARs shows that PPARα or PPARβ/δ is also expressed in all cell lines tested. Despite the 
expression of PPARα or PPARβ/δ, selective chemical antagonists of these receptors, 
respectively GW6471 and GSK0660, did not prevent their death induced by exposure to RSV 
(Fig. 1C). Similar results were obtained in the metastatic SW620 cell line where PPARγ/DN 
decreases the number of SW620 cells from RSV-induced cell death (Supporting information 
Fig. S2A). 
 
3.2. Resveratrol-induced cell cycle arrest is prevented by PPARγ  chemical inhibition. 
We have previously shown that RSV, like many cytotoxic agents, affects cell 
proliferation by disturbing the normal progress of the cell cycle [12, 20], especially by 
accumulation of colon cancer SW480 in the S phase [12, 13, 17]. To further dissect the 
PPARγ-involving pathway that leads to colon cancer cell death upon RSV exposure, we 
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explored the cell cycle effect of the drugs alone or in combination. As expected, after 48 h of 
treatment with 30 µM of RSV alone, a high proportion (~45%) of colon cancer SW480 cells 
that are still alive accumulate in the S phase of the cell cycle (Fig. 2A). Interestingly, 
combining GW9662 (5µM) with RSV (R30) decreased the percentage of living cells in the 
DNA replication phase of the cell cycle from 45 to 20% (Fig. 2B). Similarly, RSV strongly 
accumulates metastatic SW620 cells in the S phase, which is slightly reduced by a 
combination with GW9662 (5 µM) (Supporting information Fig. S2B). 
 
3.3. PPARγ  antagonist inhibits resveratrol-induced apoptosis 
To investigate the death of colon cancer cells induced by RSV, we determined the 
process of apoptosis. We have previously shown in various colon cancer cells, e.g., SW480 
and SW620 cells, that RSV was able to lead to caspase-3 activation and subsequently to 
induce apoptosis in a dose-dependent manner [14, 18]. Cell staining with Hoechst 33342 
demonstrated that after 48 h of treatment, RSV induced a dose-dependent increase (30–50 
µM) in the cancer cell nucleus size, which preceded the appearance of characteristic apoptotic 
changes, i.e., the condensation and fragmentation of the nuclear chromatin in SW480 (Fig. 
3A, B) and SW620 cells (Supporting information Fig. S2C). These nuclear changes were 
inhibited by cotreatment with the PPARγ antagonist GW9662 (Fig. 3A, B; Supporting 
information Fig. S2C), leading to a decrease in RSV-induced apoptosis of colon cancer cells 
either at 30 or 50 µM RSV (Fig. 3B; Supporting information Fig. S2C). Moreover, 
transfection of SW480 cells or their metastatic SW620 cells with constructs encoding 
PPARγ/DN protects colon cancer cells from RSV-induced apoptosis (Fig. 3C; Supporting 
information Fig. S2C) to the same extent as 5 µM of GW9662 (Fig. 3B). As we have 
previously demonstrated that in these colon cancer cells [11, 21] RSV-induced apoptosis 
involves caspase-3 activation (Fig. 3D, E). First, using an antibody (Ab) that specifically 
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detects the active form of the caspase-3 protease, with immunofluorescence we demonstrated 
that GW9662 prevents caspase-3 activation induced by RSV in SW480 apoptotic cells (Fig. 
3D). Secondly, the activation of caspase-3 was confirmed by flow cytometry (Fig. 3E). These 
results support the notion that PPARγ is critical to mediate the death process induced by RSV. 
 
3.4. Resveratrol combined with the PPARγ  agonist rosiglitazone increases colon cancer 
cell apoptosis 
We have previously reported that RSV at a low concentration (10 µM) is able to 
sensitize carcinoma SW480 cells to various chemical drugs through the arrest of the cell cycle 
and the induction of apoptosis [12, 18, 19]. Since RSV-induced apoptosis involves, at least in 
part, PPARγ, the polyphenol could sensitize colon cancer cells to PPARγ agonists. 
Furthermore, PPARγ ligands were demonstrated to inhibit growth and induce apoptosis of 
various tumor cell types [23]. However, one of the PPARγ agonists, rosiglitazone, has limited 
effects on colon cancer cell proliferation and death, up to 5 µM [24]. We therefore examined 
whether RSV at 10 µM could sensitize colon cancer cells to the potential antitumor effects of 
rosiglitazone at 1 and 5 µM. To explore the potential synergism induced by RSV, we 
pretreated colon cancer cells for 24 h with RSV at 10 µM and we then exposed tumor cells for 
24 h to the PPARγ agonist rosiglitazone (1 or 5 µM) before assessment of apoptosis. The drug 
combination was observed to be more efficient than the addition of each drug activity, as 
indicated by measuring the percentage of surviving cells (Fig. 4A) and that of apoptotic cells. 
As expected, we observed that rosiglitazone exerts a small effect on colon cancer cell viability 
at the concentrations used (1 and 5 µM) (Fig. 4A). Polyphenolic pretreatment primes the cell 
for the action of the PPARγ agonist rosiglitazone to kill the cancer cell in a dose-dependent 
manner (Fig. 4A). Similar results were obtained with other PPARγ agonists, (e.g. 
troglitazone) but it appears clearly that the best synergy is the combination with rosigltiazone 
 - 14 - 
to kill colon cancer cells (Fig. 4A, Supporting information Fig. S3). The increase of cell death 
induced by the combination of PPARγ agonist and RSV is associated with an enhancement of 
apoptosis in these cells. Indeed, we observed an increase of the percentage of apoptotic cells 
(Fig. 4B) together with an increase of caspase-3 activation (Fig. 4C), as revealed by the 
enhancement of the green fluorescence with an Ab against the active form of caspase-3 in 
fluorescence microscopy. 
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4. Discussion 
The present study indicates that the ability of RSV to trigger colorectal cancer cell 
apoptosis involves the nuclear receptor PPARγ. These events contribute to the sensitizing 
effect of RSV to the PPARγ agonist (rosiglitazone), where a combination of RSV/PPARγ 
agonist exhibits greater apoptosis induction than RSV alone in colon cancer cells. 
It has been clearly demonstrated that RSV exerts a variety of biological activities and 
its antioxidant and chemopreventive effects are currently evaluated in a variety of human 
diseases including cancer [5, 6]. As for the cancer chemopreventive action, RSV has been 
shown to impair every stage of the carcinogenic process [25, 26]. These preventive actions of 
RSV have been extensively studied at the molecular and cellular level, such as cellular 
signaling, enzymatic pathways, apoptosis and gene expression [27-29], but due to the 
pleiotropic action of RSV, the underlying molecular mechanisms are only partially 
understood. Indeed, we have recently shown that RSV-induced apoptosis in colon cancer cells 
involved a RSV endocytosis mechanism that is dependent on lipid rafts and constitutes the 
initial events of RSV effects [15]. At the molecular level, MAPK/integrin αvβ3 complexes are 
activated, leading to modulation of different pathways that play important roles in apoptosis 
induced by RSV [15]. Nevertheless, a disruption of lipid rafts and an inhibition of the integrin 
αvβ3 did not completely abolish the effect of RSV, suggesting that there are other actors 
playing a role in the molecular effect. 
Since RSV was shown to activate the SSAT enzyme involved in polyamine 
catabolism through the nuclear transcription factor PPARγ [8], we sought to explore the role 
of this receptor in RSV-induced apoptosis of colon cancer cells. PPARγ is a member of the 
nuclear hormone receptor superfamily of ligand-activated transcription factors that play a 
critical role in the regulation of multiple cellular processes including energy metabolism, cell 
differentiation and cell proliferation [30, 31]. Previous studies have shown that PPARγ can 
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function as a tumor suppressor, and its ligand has promising antitumor activity in preclinical 
models [23, 32-35]. In the present work, our results showed that RSV inhibits colon cancer 
cell viability through a PPARγ-dependent pathway. Indeed, an irreversible and selective 
PPARγ antagonist, GW9662, which covalently modifies a cysteine residue in the ligand-
binding site of PPARγ [22], partly prevents RSV-induced colon cancer cell death. To further 
confirm the involvement of PPARγ in this effect, SW480 colon cancer cells were transfected 
by a dominant-negative mutant form of PPARγ (PPARγ/DN) in which two conserved 
hydrophobic and charged residues (Leu468 and Glu471) in helix 12 of the ligand-binding 
domain were mutated to alanine [16]. Importantly, PPARγ/DN retains ligand and DNA-
binding activity, but exhibits markedly reduced transactivation due to impaired coactivator 
recruitment [16]. In a manner similar to GW9662, transient expression of PPARγ/DN reduces 
the antiproliferative effect of RSV in colon carcinoma cells. Besides PPARγ, PPARα and 
PPARβ/δ isoforms are also involved in the regulation of differentiation, cell proliferation and 
apoptosis [36]. However, RSV-induced cell death involves only PPARγ and not the two 
PPARα and PPARβ/δ isoforms, as proved by the use of their respective antagonists. As we 
have previously shown in various cancer cell lines, RSV affects cell viability by disturbing the 
normal progress of the cell cycle in the S phase [12, 13, 17]. 
Actually, it is well known that PPARγ agonists modulate expression of different key 
regulators involved in cell cycle progression [33, 37]. It appears that the combination of a 
PPARγ antagonist with RSV can prevent, although not completely, the accumulation of 
colorectal cancer cells in the DNA replication phase. Cells that accumulate in the S phase are 
no longer able to divide, and consequently will evolve toward cell death through a RSV-
induced apoptosis and caspase-3 activation, as previously described [12-14, 17].  
 - 17 - 
Cotreatment with the PPARγ antagonist GW9662 leads to a decrease of RSV-induced 
caspase activation and subsequently apoptosis of colon cancer cells. These results were 
strengthened by the use of transiently transfected SW480 cells with the PPARγ/DN mutant. 
Previous reports have established that PPARγ agonists were able to induce apoptosis in 
some cancer cell types through an increase of pro-apoptotic Bax and Bak protein expression, 
an inhibition of Bcl-xL and Bcl-2 function, or an inhibition of Jun N-terminal protein kinase 
activation [33, 38, 39]. Many of these changes increase caspase activity and apoptosis. 
Moreover, others have previously reported that PPAR agonists exhibit antitumor effects [30, 
31] by inhibiting the growth of various tumor cells [23] or by inducing apoptosis [40]. The 
clinical trials to date have yielded evidence suggesting that PPARγ may be suitable for 
targeting in pre-cancerous and cancer cells in select tumor types. Thus, pretreatment of colon 
tumor cells with RSV synergizes with PPAR agonist to induce cancer cell death. Altogether, 
PPARγ could mediate a part of the chemopreventive activity of RSV in colon cancer and the 
combination of RSV with PPARγ modulators. 
The screening and identification of natural compounds that retain PPARγ-dependent 
and/or PPARγ-independent anti-cancer activities could be a useful approach [41, 42]. 
Alternatively, development of “non-agonist” modulators of PPARγ that exhibit improved 
safety profiles [43] might be a suitable strategy to explore. 
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Figure legends 
 
Figure 1. RSV inhibits colon cancer cell survival through a PPARγ  pathway. (A) After 
24 h of culture, colon cancer cell lines, HCT-116, Caco-2 and SW480 and their metastatic 
phenotype SW620 cells were left untreated (Co, 0.1% ethanol) or treated with RSV at 30 µM 
(R30) with or without GW9662 at 2.5 (GW2.5) or 5 (GW5) µM for the indicated times, and 
the percentage of cell survival was determined using trypan blue exclusion. (B) SW480 cells 
were transiently transfected with either an empty plasmid (pcDNA3) or a plasmid encoding a 
double dominant-negative mutant of PPARγ (PPARγ/DN). Twenty-four hours later, cells 
were treated with either 30 µM of RSV (R30) or with the vehicle (Co, 0.1% ethanol) for 48 h 
before measuring cell survival. (C) SW480 cells were left untreated (black bars) or treated 
with RSV at 30 µM (R30) (white bars) with or without the PPARα antagonist, GW6471 or 
the PPARβ/δ antagonist, GSK0660 at indicated concentrations (0–5 µM) for 48 h. Cell 
survival was measured by trypan blue exclusion. All panels: mean ± SD (n=6) of three 
independent experiments; *, p<0.05 and **, p<0.001. 
 
Figure 2. Accumulation of tumor cells in the S phase by RSV is prevented by PPARγ  
antagonist. (A). After 24 h of culture, colon cancer SW480 cells were left untreated or treated 
for 48 h with RSV at 30 µM (R30) with or without 5 µM of GW9662, then stained with PI 
and analyzed by flow cytometry. One experiment representative of three is shown. (B) 
Quantitative analysis of colon cancer SW480 cell distribution in the phases of the cell cycle 
(mean ± SD of three independent experiments). 
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Figure 3. PPARγ  contributes to RSV-induced apoptosis in colon cancer cells. (A). SW480 
cells were left untreated (Co) or treated with 30 µM RSV for 48 h (R30) in the absence or 
presence of 5 µM GW9662 (GW5) before nuclear staining with Hoechst 33342. Original 
magnification: ×40. (B) SW480 cells were left untreated or treated for 48 h with RSV at 30 
(R30) or 50 µM (R50) with or without 5 µM of GW9662 before Hoechst 33342 staining of a 
pool of detached and attached cells. The results are expressed as the percentage of apoptotic 
cells (mean ± SE of three independent experiments in which each percentage was calculated 
by counting 300 cells). (C) SW480 cells were transiently transfected with an empty plasmid 
(pcDNA3) or a plasmid encoding a double dominant-negative mutant of PPARγ (PPARγ/DN) 
and treated 24 h later with RSV at 30 µM (R30) or 50 µM (R50) or the vehicle (Co) before 
measuring the percentage of apoptotic cells (mean ± SD of three independent experiments in 
which each percentage was calculated by counting 300 cells). (D) SW480 cells were treated 
for 48 h as in (C), before staining with an anti-active caspase-3 Ab (C3a) (green) with nuclei 
counterstained with Hoechst 33342 (blue). The arrow indicates a typical apoptotic cell. 
Original magnification: ×40. (E) Caspase-3 activation was studied using an Ab that 
specifically recognizes the active form of the enzyme and analyzed using flow cytometry 
(gray, control; black line, treated cells). One experiment representative of three is shown. 
 
Figure 4. RSV combination with rosiglitazone, a PPARγ  agonist, increases colon cancer 
cell death. (A). SW480 cells were left untreated (Co) or treated for 24 h with 10 µM of RSV, 
then exposed for 24 h to the PPARγ agonist rosiglitazone (1 or 5 µM) before counting the 
percentage of viable cells after crystal violet staining (n=6, three independent experiments). *, 
p<0.05. (B) As above, SW480 cells were left untreated or treated for 24 h with RSV at 10 µM 
(R10) and then exposed for 24 h to the PPARγ agonist rosiglitazone (1 or 5 µM) before 
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assessment of apoptosis in a pool of detached and attached cells stained with Hoechst 33342. 
The results are expressed as the percentage of apoptotic cells (mean ± SD of three 
independent experiments in which each percentage was calculated by counting 300 cells). (C) 
RSV/rosiglitazone combination synergizes to induce caspase-3 activation. Active caspase-3 
was assigned the color green and nuclei labeled with Hoechst 33342 were assigned the color 
blue. The arrow indicates a typical apoptotic cell. Representative cells of three independent 
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Figure 1, Aires et al.,  
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Figure S1. Relative mRNA expression levels of PPARs isoforms in human colon cancer cells. 
One microgram of RNA was reverse transcribed using the M-MLV Reverse transcriptase kit ADN 
RT-qPCR was perfromed using the Power SYBR® Green PCR. Amplification of specific transcripts 
were confirmed by melting curves obtained at the end of each PCR run. Standard curves were 
generated from pooled cDNA of assayed samples. All PCR efficiencies were between 95-105%. The 
relative changes in gene expression were determined using the ΔΔCT method. Fold change was 
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Supporting Information Figure S2 Aires et al., 
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Figure S2. PPARγ dominant negative mutant and GW9662 antagonist of PPARγ inhibit resveratrol-
induced biological effect in metastatic colon cancer cells SW620. (A) After 24 h of culture, SW620 
cancer cells were left untreated (Co, 0.1% ethanol) or treated with RSV at 30 µM (R30) with or without 
GW9662 at 5 µM (GW5) for 48h or SW620 cells were transiently transfected with either an empty plasmid 
(pcDNA3) or a plasmid encoding a double dominant-negative mutant of PPARγ (PPARγ/DN). Twenty-four 
hours later, cells were treated with either 30 µM of RSV (R30) or with the vehicle (Co, 0.1% ethanol) 
during 48 h before measuring cell survival using trypan blue exclusion. (B) After 24 h of culture, colon 
cancer SW620 cells were left untreated or treated for 48 h with RSV at 30 µM (R30) with or without 5 µM 
of GW9662, then staining with PI and analyzed by flow cytometry. One representative of three experiments 
is shown. Quantitative analysis of colon cancer SW620 cells distribution in the phases of the cell cycle 
(mean ± S.D. of three independent experiments). (C) Treatments or transfections are realized as in A) and 
apoptosis was determined by nuclear staining with Hoechst 33342. Original magnification x40. The results 
are expressed in the percentage of apoptotic cells (mean ± SE of three independent experiments in which 
each percentage was calculated by counting 300 cells). For panels A and C: mean ± S.D. (n=6) of three 
independent experiments; *, p<0.05 and **, p<0.001.  
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Figure S3. Figure 4. RSV combination with Troglitazone, a PPARγ agonist, increases colon cancer 
cell death. (A). SW480 cells were left untreated (Co) or treated for 24 h with 10 µM of RSV, then 
exposed for 24 h to the PPARγ agonist Troglitazone (12 or 25 µM) before counting the percentage of 
viable cells after crystal violet staining (n=6, three independent experiments). *, p<0.05.  
 
